MannKind Ends Phase 3 ICoN-1 Trial for Nebulized Clofazimine After Futility Review

MannKind Corporation discontinues its Phase 3 ICoN-1 trial for nebulized clofazimine (MNKD-101) in NTM lung disease after futility analysis shows no efficacy. The company will focus on developing its dry powder version, MNKD-102.